0001457612-20-000120.txt : 20200723 0001457612-20-000120.hdr.sgml : 20200723 20200723070652 ACCESSION NUMBER: 0001457612-20-000120 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20200723 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200723 DATE AS OF CHANGE: 20200723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENOCEA BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001457612 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 510596811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36289 FILM NUMBER: 201042726 BUSINESS ADDRESS: STREET 1: 100 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-876-8191 MAIL ADDRESS: STREET 1: 100 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: GENOCEA BIOSCIENCES INC DATE OF NAME CHANGE: 20090304 8-K 1 gnca-20200723.htm 8-K gnca-20200723
0001457612false00014576122020-07-232020-07-23


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________
FORM 8-K
_______________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 23, 2020
_______________________________________
gnca-20200723_g1.jpg
GENOCEA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
_______________________________________
Delaware 001-36289 51-0596811
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer
Identification No.)
100 Acorn Park Drive, 5th Floor
Cambridge, MA 02140
(Address of principal executive offices, including zip code)

(617) 876-8191
(Registrant’s telephone number, including area code)
_______________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.001 par value per shareGNCANasdaqCapital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§ 240 12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.
On July 23, 2020, Genocea Biosciences, Inc. (the "Company") announced its financial results for the second quarter ended June 30, 2020. A full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  GENOCEA BIOSCIENCES, INC.
   
 By:/s/ DIANTHA DUVALL
  Diantha Duvall
  Chief Financial Officer
(Principal Financial Officer)
 
Date: July 23, 2020


 EX-99.1 2 gncaq2pr.htm EX-99.1 Document

genocealogosmall17kb1.jpg


Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com


Genocea Provides Second Quarter 2020 Corporate Update

Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDT
Filed IND application for GEN-011 and is working with the FDA to provide additional information
Private Placement with Leading Life Science Investment Funds

Conference call today at 8:30 a.m. EDT

CAMBRIDGE, Mass., July 23, 2020 - Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the second quarter ended June 30, 2020. Genocea had an active and productive second quarter, demonstrating important progress across the Company:

GEN-009
•On July 30, 2020, the Company plans to present initial clinical data on the first 5 patients from Part B with Dr. Maura L. Gillison, MD, PhD, Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. Part B of the study is exploring the combination of GEN-009 and immune checkpoint inhibitor-based regimens in advanced solid tumors.
•Presented long-term follow-up data from Part A of the ongoing Phase 1/2a clinical trial at ASCO20 Virtual Scientific Program that evaluates eight participants for duration of immune responses and clinical outcomes.
◦Seven out of eight patients treated on Part A of the study are without disease progression at one-year median follow-up.
◦ATLAS™-identified neoantigens generate broad, sustained T cell responses starting after only 4 weeks and lasting for up to 1 year after the last vaccination.

GEN-011
•Hosted a virtual KOL symposium introducing GEN-011 – a neoantigen cell therapy that uses peripheral blood T cells and is powered by ATLAS™ to target the right tumor neoantigens. The event featured commentary from Dr. Eric Tran, Assistant Member at the Earle A. Chiles Research Institute in the Providence Cancer Institute and members of the Genocea management team on GEN-011 as a new category of T cell therapy designed to improve on current limitations of TIL therapy.
•Filed an Investigational New Drug (IND) application to initiate a Phase 1/2a clinical study of GEN-011 evaluating patient safety, T cell proliferation and persistence, and clinical activity. The trial expects to enroll up to 24 patients and will assess GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy. The Company has received verbal notification from the U.S. Food and Drug Administration (FDA) that the agency has completed its review of the Company’s IND for GEN-011. In this verbal feedback, the FDA informed Genocea that it is placing the IND on clinical hold until it receives additional information pertaining to certain third-party reagents used in the GEN-011 manufacturing process. These reagents are not a component of the final cell therapy product. The Company expects to receive official written communication from the FDA regarding the hold and the FDA’s position in the near future and plans to work with the FDA to resolve their questions as quickly as possible.




Private Placement
•On July 22, 2020 the Company entered into a private placement led by an undisclosed leading U.S. public investment fund specializing in life sciences as well as certain existing and new investors providing for the purchase of up to approximately $80 million of its common stock and warrants to purchase shares of Genocea common stock (before deducting fees to the placement agent and other offering expenses payable by Genocea). Genocea will offer 21.4 million shares of common stock and 12.2 million pre-funded warrants to purchase common stock, along with accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant purchased by an investor. The warrants will be exercisable immediately upon issuance, in whole or in part, at an exercise price of $2.25 per share and will have a 4-year term. The closing of the private placement is expected to occur on or about July 24, 2020, subject to customary closing conditions.

Shionogi Material Transfer Agreement (“MTA”)
•Entered into an MTA and exclusive license option with Shionogi & Co., Ltd. (“Shionogi”) to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. As part of this agreement, the Company received $2 million for the exclusive option to evaluate the HSV-2 antigens and to negotiate a license prior to expiration of the MTA. Upon exercise of Shionogi’s option, terms of the license are expected to include an upfront payment, regulatory and sales milestones, as well as tiered royalties. Final terms of the license agreement will be based on results of the MTA evaluation and overall diligence. If licensed, Shionogi will assume responsibility for global development and commercialization of the HSV-2 vaccine product.

Inhibigens
•Presented preclinical data at the AACR Virtual Annual Meeting II that furthers understanding of inhibitory antigen (InhibigenTM) function and builds on previous research demonstrating that the presence of an Inhibigen in an otherwise protective immunotherapy can be detrimental to anti-tumor responses.
◦Inhibigens were found to alter the tumor microenvironment and drive tumor hyperprogression and also abolished both global and tumor antigen-specific T cell activity to beneficial anti-tumor antigens.
◦Findings suggest that Inhibigens must be identified and excluded from the rational design of cancer immunotherapies to achieve more favorable patient outcomes.

“We continue to advance our clinical programs for patients living with cancer,” said Chip Clark, President and Chief Executive Officer, Genocea. “I am pleased by our ability to remain on track during these uncertain times, meeting our highest priority milestones and working to deliver on the promise of developing effective immunotherapies through our unique and differentiated approach.”

Second Quarter 2020 Financial Results
•Cash position: As of June 30, 2020, cash and cash equivalents were $22.1 million versus $40.1 million as of December 31, 2019.
•Research and Development (R&D) expenses: R&D expenses were $8.6 million for the quarter ended June 30, 2020, compared to $6.8 million for the same period in 2019.
•General and Administrative (G&A) expenses: G&A expenses were $3.5 million for the quarter ended June 30, 2020, compared to $3.2 million for the same period in 2019.
•Net loss: Net loss was $11.3 million for the quarter ended June 30, 2020, compared to $6.5 million for the same period in 2019.

Guidance
Genocea expects that its existing cash and cash equivalents inclusive of the private placement proceeds are sufficient to support its operations to mid-2022.

Conference Call
Genocea will host a conference call and webcast today at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 8894505. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations. A webcast replay of the conference call


will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

GEN-009 Clinical Update Registration
Genocea will present a clinical update on GEN-009 on Thursday, July 30 at 8 a.m. EDT. Interested participants may access this event by registering here.

About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and expect preliminary clinical results in the third quarter of 2020, and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood for which we expect to conduct a Phase 1/2a clinical trial. To learn more, please visit www.genocea.com.

Forward-Looking Statements
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.


(Tables to follow)



GENOCEA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands)
June 30, 2020December 31, 2019
Cash and cash equivalents
$22,108  $40,127  
Right of use assets
11,265  6,306  
Other assets
7,143  6,178  
Total assets
$40,516  $52,611  
Debt, current and long-term
$13,627  $13,407  
Accounts payable and accrued expenses
4,749  5,164  
Deferred revenue
1,094  —  
Lease liabilities
11,526  6,512  
Warrant liability
1,483  2,486  
Total liabilities
32,479  27,569  
Stockholders' equity
8,037  25,042  
Total liabilities and stockholders’ equity
$40,516  $52,611  


GENOCEA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
Three Months Ended
June 30,		Six Months Ended
June 30,
2020201920202019
License revenue$906  $—  $906  $—  
Operating expenses:
Research and development
8,587  6,849  18,574  13,309  
General and administrative
3,480  3,217  6,868  6,234  
Total operating expenses
12,067  10,066  25,442  19,543  
Loss from operations
(11,161) (10,066) (24,536) (19,543) 
Other (expense) income
(160) 3,571  362  (2,519) 
Net loss
$(11,321) $(6,495) $(24,174) $(22,062) 
Net loss per share - basic and diluted
$(0.39) $(0.42) $(0.84) $(1.57) 
Weighted-average number of common shares used in computing net loss per share
29,142  15,344  28,642  14,035  


 EX-101.SCH 3 gnca-20200723.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 gnca-20200723_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 gnca-20200723_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 gnca-20200723_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 gnca-20200723_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 genocealogosmall17kb1.jpg begin 644 genocealogosmall17kb1.jpg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end GRAPHIC 9 gnca-20200723_g1.jpg begin 644 gnca-20200723_g1.jpg M_]C_X 02D9)1@ ! 0$ 0 ! #_[0 L4&AO=&]S:&]P(#,N, X0DE-!"4 M !#4'8S9CP"R!.F "9CL^$)^_^$)4&AT=' Z+R]N&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI M2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O " @(" P "0@* 0<"!@0%"__$ "\0 (" @(" 0," M!04! 0 0% P8"!P$( D1$A,4"A46(3%1L3)!87&1%Z'_Q > 0$ @(# M 0$! !@<%" $#! D""O_$ #01 (" @$$ @$$ 0(%! , (# M 00%!A$ !Q(3%"$(%2(Q02,6,B0S0E&!"1=BD<'1\/_: P# 0 "$0,1 #\ MO\>.G1XZ=> T:+4BXUNX8 JE2X:4Q@R9%C@+P1(,>../GSM2EUEJT5U,>]QBM24K-K6L*>!!:UP1F93]"(C)3/U$3/ M7Y,P6)&9" !$D1F4"(C'W,D13$1$?W,S$1_?7JZM<*G>$\5AI=FK]N0SRRPP M.JNZ66%3--!SQC/%$R3E&A220Y<\8RQX3Y9Q\\\<9XX\\^=UVA>QKRJY&G:H M61$2*O.?Z>>3KMZ/'3H\=.CQTZ/'3H\=.CQTZ/'3H\=.CQTZ/' M3H\=.CQTZ/'3H\=.CQTZ/'3H\=.CQTZ/'3H\=.CQTZ7-W]W)WIHX^K]:=#>O M2K9VR-ILW0S[;FQ"AH--Z.0J,5L?[M, MY %$UM=K=?[:9(\UF.YVUOPN'PB:YUL#B5F>P;):?+I]&/.:UA*$HA, ]AC$ MRRRB";63#7C%]DO;#7BG4UW&+N6KALAEVT411H+" _>^/8LB,Y.96,>4<++@ M6'(A,"/=CWKOO470^JM1W/K%KSLPBWQ5&"/<=IV6EL8^@,VE:BKF1]<_A]*3 M.PC>Q^YY;3[.L756-? MHX>Q4/:81#J=I_P!.;79-GZG; M*Z=4+VV\Y[\@$8>EO.'[@9/7\'1V,KV]KKWJ>-QE>W*XU_-8FLJ MY7>P;%H&%1IUU0:+X76!2:1$&+Q^PX>EHYVWX:YA*]ZX['PG#$Q3K%@TQ/S: M=II*8 ^M4C#FL+@T2H9<,1$L)].':34^Y^M%T'K7:C=>_P#/55K-(L1O:E+5 M*QN75E/;J\3Z^BN3ZNG'([E7(8T[]@IV'*[8_DQX,U1A(&*+%8#5/Y :3G=> MW'''R7PW3+"RZU*O5$F'DL'L69K>K_&PPM>PHGDPF0A< +A%K M)>X7@ME)P;-6S$&8+62\F T!@"9#@0(:$8-)*,6(5!)',.2/+)!/#GA+%)GA MECES03E-KM:AZV)P#=_8'1VCTQ M_5W5^6U=X;$VUK'4E*5DI6SVN5G*[ON8WEYN8:B8.6"K5FNKVDYC QHI5 &D M+R69^ D!8BI\S(6KM2D@"6;%*^0SAEA\!(S"5*$ MY(B, &9&3*!YB4A;#]EG<^X^]*D=0-3-)DVC:!M5'KBZZP'K"0[*WTR.D!VW M:NS;>U-7$V .)2N8R,ZH6L9J%2D%2ERDB/)>F?F;'XKL]V\Q_P"-.2W[.I&Q MLN5PEG+X[,G/K7 JOJ0INUPRL6. 7&4, M-NTS)EGE#F&!_#?%3JU>QDMMS%+=+./"R+<>-4<)C;ST>U=,U$OY]Q*3,:]N MV%VH1^+&(3 ",,Q=WNQ9C)&NOBZCL2#Y60O]LW+"0/QEHE!>E1G$2:U$AL1$ MB)GSSXV">Z^X>LSBAXZ'W+IT3>5:O%?3.W6NG(XBY4G4S\8EU\HPV;CDU#8Q M9(N"TO*'$=NGD'X,@/7,9C<,G.YON&FO.2<. R57&U ML30M,;7"N92U:QF% MU>7E20_)U+%UV0MH%;&C2I5C00+I^Q8MNG91ZGEZJT-8MWKU]T^T%ZX]/=9= MZMM0:_1:7U1L-&Y2]D2-@71P22,B&K[->8MMESN=E;,.#24S''9#M/^7>P?F#C=7W?"Y+,Y+.:[F@QE+6V8S'JRF!V13*-Z%*Q M^%0-:^=[PHVZF02#/G(%:SA#J[ZE>J.XG9 .Q>5R6MY=-!5+)4?G#EZ]FR=' M*XEGR*T.]]XH?6]!1818J-\"K.YF/8MBW-V/ZLNN0W5WJX/K2I=BUG9C2,U[ MM-KZXW=5(.8,DTK8\%A2&F<.%[ALE=\I7L=C)R/1?@*>)&$L :M7C'DN%N[O M7MI[INIYB_J3M-V0<92H[=C7P:SL[%4EP6LC\=M=%BM\FK-,859]K^%03'N\ MH<=:ZABXQ.(BJG*#EJ$V7/Q=D>)@*+? EH]@L-;/!OM+R7XAR<^(!_L%D'E1 M]2GJ!7>;V0=8_7W6$K?>5C:EVFV8&24G5]'706#8=LA7Y81',1%HKX, M\L0YEEL;10EP*DQ!&*,998@Y6?VU[1;GW4N6$:U42%&C*QR6:R33JXFB3>96 MECQ4YMBTT8(ETZB7V)"):8 F)9$/559BLQK>=)MF MM7M*0W(4FTPLN6DKI#;I_P#$4ZGG+KGF^H1W&L-PS&QS7;K\9NX?<'&5<]'Z=KF$O##:%O-G9BUD4%_LLTL;3KV M+1U63S*K%CXJK \'6)RY@I\>>[B8+!V&4O\ B+]Q,R+UTX5ZD'$?N6ZPXP7# M!_ZEK]A!/[60$_4ZXZJ?J(>DW8V\H=<6U9L#K[8K6S&35ISLKBK,==LW!T\8 MB]03>ZF\9AUTP\R6(46>SKE";,F6(:1O$1-#%)E]W_%#N-J.-M9>@[%[54HI M.Q;J-G&M< M8K4RWZ3JFPY\07-A##%1$4Q$2X%KYXCS@IB.IU=]_91H;UU+-8-=XH-H/AML MM+4IK>.LZZAL$HI-0 4,&>3G%[:JQB)#+"Z$Q#R&S-SEEPGQEP@QCQRDK3M? MV@V?NT[-(UJUA:IX)-%]R:U&[)D)5SED'"X&)'B2YF(D.Q M[7CM8&F>05<9%TW J*BEMD90*R/SACE<1PP?&1DN9YYXC[Z7=L7]25T?JVO: M5;J;3MU[#M%SC=%RZX$2U% _I*].].10DWUL?;"ZZG)L.8$S6NIE9[UR0BS% M;- E QP/)-L8G\0NY-W*Y&AD2ERWQDU M !,82_$S%<$/,R?7M[*FBM\L681G-9W7%;.;:]:'U;J5^ MTZEJ @S5Y0)-2Q1FMH 1")Q$B820R0>)04[8[N>RCJIT"4J)M[W([.X64.9A M4]64=9Q:-D61T9)-.N'NM-&)XDX7R(@OGF/:TUAY1(C)%$QTHRM?J@^I["QQ@V M?K]V*J]8EG^WQ98,-;60B"+++XQ*+KBZX#G M5\7/POWE526TMIU.[<$?+X93EZ8&4?R"[;J!JYG^!)H*#G_<0QR40I7=S#$W MQ=CNQVENU6L$NXM"WU-L.@N MY"!86RKF>$EH[ M%I&:L:_M&+L8G*UH R0^!('(9SZK52PHCKVZCH$I39K-:D_$A@_,#$;)QF4H M9BH%['6 LUF3(P89ZBF?[@X/!6&4I]]^ZKZ0JM1S9),%[M]CMA[1AB;.4RN&R]#-.MUZ=C&%;!P/HK0YX M6:MRNDECZ["R6Q;' ?[XF0D8B?7J^Y4-HFTNM6N57TQ4;@LPJ1D'$8A*V)8< M%^X"@H(0F/J8YB9XC1VQ_4*])NM=X?ZUJX-^[!6NIL2E%G/UA'60Z E;@3R" M,5'-]M;Q6N=L%Q<>0AN57">*QB\9@Y&G!@\P\?@[ MB?C%W#T'%VL]!8W9<-0"79!^%.U%S'UPCEEJWC;M:O9^*J."<^M-H*XI M(RR._!=QL%F[*J7%C'VWEX("Y"O58.?H5JL),URTY^@!GJ\RX%S_ M >AT\U,XW/ORZ"TVEJYX%PO/XY#-[9; ;A-FLJU2KX.$C*PV1GP//D*M!B MR^T,.6Q83 JPC3AZ*:M.JN1AUV_:9,)J5$ M^0P;FE')D"E"QS%J.69;,8_!TCOY)\(KA,!'U),:THF02E0Q)L:?$\ ,?401 ME(@)%"-:I^ITZ>?&'%N\J%;$)<38 M"/Y+P]IQ'/ EQU);3'OTZ3[Y[!47KGKZM[Z+M>Q]A9ZZJEF.I-2%HQ[#F5GB M&\Y:1W\AO'7&0ZS(\$OE%R?F(4)E.M'FSF@AA^Q?B[W&U?534KQ3+*WHG% B;:2="V!\KUPP#@6D,019:AW(P&1R5?%UE9&76K M4U4N*NF*Q%R7BSV19D_4<#Y#/K\O&1Y")Y&)J]FNQ&W=0=CNC>M:/0(;5K7? MVQMM5;=%HR4NC"*&BIFH7%YK[$5DOD_;TV1#%:8:9.Y&*&/6I#%(>,)Y<)$= M=:;J>!S^H]RZP*V:IWBK%%@NA&A:A8<4QJC4[>:EH=+$[1L&R!E6U5A?82AVV5S2P97)0XW(Y6A:?%*XVHLD1;^,F MW8$&0N\Q\-+KR8/%=NM6Q5]D6+-&Y5%J[(.7:]C*]A(O6Q;I4X42D#9%WN/Z[=X6 MSUD[VT;J\L2T;LO=BH-_+J*MI N56=;0K37W,VO5S5Q(L#).,5*R3("&>0"U MD]B$79YCB\QF<[V_^F1VJH?B/D-9+4U%ML:Z_EQW'+OB^?\ 2U&Q6Q>%QZ*6*5>E M*;^5@O'0OL*Z7ZR]:.CRJT5#2 MKCM_M5;NW%\.R!<661H8'2:.AW/*U39F\E3R":>=MUJ;!45H)IR- M>/FI@PQJ2N M9",AK%K&.V;!4]4QY*+T/O9AV;5_C:--#4$VDMCADH64-Y9_ MA/CY)0J2*.8FQ=SSEQ'SSS_++C#GGG_?CC+C'Y_SYJ9'W/']<]6A_7_]_P#O M_P#/_GKYM_MQO=BW5[3NQ:^]O\E"ZO[?K>D4AQ_/.2^F:^K,=>KXAL(\N7$4 M*X;EJ[NQN&/T1%%M&!DW//).IKEYU='QK-&@VRK(38<36MKJDQ]_DSU,&P0P! *X&)9'I@)@>D3^B2ZV#7& MU.\>QJK]<-IH?KEW[=J[QQCQ))&_K#:DO%&/T<\<\29Q,0Q\N., M?J)_\]5W MV[L-JW=ALIYAU?5LE85'$3,-2RNQ?U,??!1'U_?_ &_KJ!/0J3=I_8Q5/O:*8HN<"!GLET@BL5>_?6:=JZQ*%G9F&BPNWD;B8 M AA $2+:'<\=<5J3\?L&Y7.W>$MVJF._6,1:5B[(@ --.'KVIJ6OC(L(K2!B ME:S*M6FN+ 2; ..ZY-\LH#Z.)5GKBELL?$M+*PN2*0AEMBH:KV&LV3,292,, M9!R,G S$\.Y?6;V6=S[E7KU8?5/CI.R*DQR%X9H/5I51&O0),\,H)%R7'7IN MO/;H\,2Q%CD: -E(N/D 8D&C!K, JR[>[CV?[>8^WC*O>_\ U'3?85:K+VC- MKOGC&@)0T<>U>,0U:+4R#'5S-B8:N&J!9L?+9%G,5M6>L*LMT[]/:"R6PL=3 ME$61*8\9L"5DQ(UQY"#!B#D"\2DH .)&^YV7H46MQE/\,)R?J:M%RH%H9-F1+*1,;D1-GS++GY$/QZ'7H[L= M]SU2W4NZ\^YAK>*L4"DJ15[M_)6Y"K,B'"$M>Q"Q@1$!7 C'C$=97>OG?Z9T MN,FMBKZTW%65NCAL&E%94$R.9_>8 )E]\S)F?8GUU9[3W;J M!!L+8NW'^W5W-T=2,N7](4U:P-J971J*4,KN%J?=J,'KF?M8K$X*K@6QCJ\)^+D7W:B,A;/)K-9SR3]M<$L-"AKE!1ZI#PEOF/!$ M9?NF1B!A,OH>*-4>U7KF&*5+CB4+NM PRX^,?SU^.H;Q+-$1AC\8982EJPC> M<...,,"!X9,,<>8L/IV%_)Q:['9';6&L>09KMI4?SZF_KV-&""9^XD01LI MII./U'&2RY_MQ5JZ9V3UQV%HA:FAH8[)%5$<%E,I9PQ9RW)2ODS==NEZ2(?) MGJ%2P^E+B/#GVLRVX9 +CR7[\U./]AS]5JR[<4U?4\1 I3'EQ_$EY%/^Z>;) M'LB]*WK^TET$W'LK5-)8ZRV7HK7A-S2[*-OUM=LKJRK^0L>:&^ OW!E?;97G M.3)8/RI3I"5KY@OD0<"BQ/K2\+4V M7L-Y+D8]=@6F2C^1SXQX N180RK@8D)3SZ.>Q6TM)%^P<&CF,)%:SHCN7>P: MO#ZB %^SM,CKHZ19OQ,N,X<3?Q;,>L)DQPXS.$% 'GYSC7C8Q7_^2>I838U] MJFY):H<[N;K^LL=/ M;A=A-TY*GY\P4K\Z:G!$_2S-QCP33\H1V^R=N@6RC7 M(I -=O9&!C[$;=#Q^.WC[CR\7$,S_8B,3S QU'7TY]6]4]VN]%=USV)8&6&G MP4N^;7?H"7ARYCM>PHB$TV2)B[#)' M!$M83BM'Q%//["NKDR)J(KV;K%RPA.XQ4A,K(Q*&>)DV7.\2@S$#CRB"*>K: M_;?JMU^]>'2WO;OOIIJ]=I78=BZTLZDSEHI[H=3Q &28 KL0B4IB<"JL->BM MS=A@[5X!F2_:AF-RGE#'FBT3T3=]J[L=Q.V>K]PLT[8\34W!-](Y-52%<"+#$KHS6'QNL8'8LE@J@4+3<2:#FN3!#@9(0 M<*Y(A!JH>9>P/&9^IGGQB8IO^MK/?U=W+8KIUOZ947N==:54((\:ML*G'7Q+ MKD1NUP"%NP* :T5H;]^(Y F1+FQ_+/);!,?F# (63D9Q] ^[\:M;UZIC=O[A M9+M[CLC?*?FXK(*QEC+,0B6'CF6CI7#BJ'MBRU"_3[B%7L(UAZYHW5OU)5]K M\7@J^>?73$>FR@K(5A,_$; KARA]D^,J R\O")/QB"GGJ1W:_J/[,.T>V,=R MQ^L)WH"VY)P!F0G7S7150KSNPIS)SE=Y,5'WAQ$%=(:MM-#Y#32S:LNN_;K5;"Q4_&K>K&H)N/+_(0HL0 M[U^]RUD*2A8Y3,X7;,O=^?&I-QKO6,$.-K376QH%)!8("L' OB>(E@2/EX 1 M1)C,EO7]0!M;=-MN/1&A[=%>5]JIZ6Z^V?;JDUP_%G!W1L@LY/LV9@%%GF-B MZ5STT9%+],D_(7&; >.7' R;&2,_BS@]=H8_N;D\"RM:0_N)E<-0O(_>+->Q M +L8:%,*!.:[QR!VAY@/9,),H\EC,9'N1=OO?KM>[#%F& JVWI/]LC>M$06Y M./L88,H%<_<\1)1$\%/+7?71Z4O7[NGH+IK8NTJ6QV9LO>FME]W=;/ OUN3- M*8TLV$V6*.AA(W M<4_P++QPKFX:I74[%VN826'@P>7]M'HWNW^17=37NZ.P M8G"Y!6&PVLYAN.KX5N+H6$9!-.1&;.3990=M_P"I#_G'T6:XIK.5%25F/N*9 M:OH6M7];D^Q&X9-]8J3\CH*<@^F?/E4==5C;3:I>7[N:YM)4^ M7[OV?NX+F(J[64C6W3%5P9#@1G)2#HXX:"3L*%GU]?Y("#^N8^_J>.OI&6^Q M@T^JV6VLA61R^K5]U8S@DP>;%L8&C6%-"A5BZ/./,]@1 ))"$%CGCD63G$/Q MEQS)\^?(>A49D+U.BDTK;=M5ZBV6&0I"V67 @#L/?/4KM+M/IWBVJ5 M"[LTF^T?9-H>M&7\0Z?@+!9EN:,-7K&?^/KY?27#_FTD5?(Z96=!FK)XM*PF_RB_D^W&2Q>2P].LE7Q,^2V)"ODCMTU0>4;D:]6*0 MW?4+UE#P^.J[\H2@.#P>I9'"YBY@X-%?/HLU[3F&7MI1(G)UX6TO&L*#9+I5 MY2!QX%[#3ZIA?'J*].&V]%=RT'9U_P!@.O\ L75>G>+TNK;G0]\)O!6Q7=GJ M;:H0P,X!E\"^FJQ%CTINZ5&.73&1@."K%P)"^ZXXM7OS^0.!V;M]:TRKJNTX MC-Y_],;;K[-C QH8FM2O(R!&DC:;L@YCJH(K/77KJA1M<"JMVVJ\MM7(OME<:..A2K$K&K#)^'--H M\*4F%>!$T6+\&>PG$)P?3E?>);/8!4-&^OSK?0V6X7=FO5+@5;DM>EY+?R_V M?O\ J=;H25;62[)3N(6T([!T=9K<*-*8N L)\<;DO',>O2<"Z]_C91[67]E[ MI[=DTX"M2QF0)^OT=BC'_&PNKWK>4L.N+IY#R01*KJIT&&*W-JJ*:Z^"M#YS MGN _9$8_6<57.\QUA$!?=1]WLN9)*JRQ2341#(@F&UXQY"+2B&%]*^G(==K/ MWJX[(:UTWLZL9B:)T[T?U=GM[;#U9$P,W)VSM,:,-K!5;9E/\EATP*N66>RQ MK(,X)F+W QR3];"O01Z_;92[:?Z1R^PX:Y![-L'7[BF6_[T],[YXXYXYXY_GQS_+GC_CGRFNI9U5-]T/I7V3V+W$U[ M5]2.:O8KS<@50>W]-.;$DJC)\]1+!TJ^[T=L[(!KLS!@@!6K+16GYZ?DLE8( MY5,R3#F"Z3=_\>/R(Q&I8!&D;U%VIC<>US,!L->I9O)K5K3RL.QN216!ML4I MLM N.N] K6IT4[OFAVLI>/,87U-L/$!NT6-6DV,4$+"Q7-DBJ2)8 MB+DL)?E(0P#DB(>E$V7H9[@#NMNQ1.RUKVYJOJCU\UK9-@'5;=&[^7E1F&UX MF):U^I4[7:"Y6:9T<6>,&JK7#>(&JUZ4B L8N*2 ,$B^:7<[L&K;\0>G4,#F M]XVO,4\6J[KNMQ7O@>6L BW?OY>UCZ8UEK4;'W/03+UL0(# A-C A+=7Z9VO!V7N5 MOU4Z5PM$##J1:TM@"+PXD!)"?[+UN!.M,QY^/N1,1<#QLX_CYEAPG_E\8\_$ M:_,:VRGV^U=U9Y)M*WNC8JL7,BP65NKEMLFH)F# MDC7;BH'U C9%4J[[[D)&O-AZ]O,PBB]*X ?MJI&"B-X%8! 0&IRJOO(H^(,= M@/R [2=UM/C6.[,(P^0L*KAE:]]5\,1>NU8@@RN)RN-%EC&N)O+X4\JS*K&- M0I]NL4^7HO:/M&LY7]2UCSM(61_&-!)FVE+/J:MJK8D0LC \!)![0:(@P@6R M(X]LFZM^_P#[];>K[;=UWV]UIK((XB!G<3[:)I&K5FOX$REFDH-2ZBLH#6ZV M:?G.:6"9B!QP>7B(&SM2I1#'C!T6-U_%KM=@+2-IN1CJ8Q B0I;,J"6,31?8(I/]AA^Y.R75'?L7<2H8A9O)XT$I5SR M1+IT7 ;VS,S,20_NF!@G $?3#O=-ZVNRF^]%='=0=5Z;9=VX]?8KNDM3ZX[' MK,%M)#(I](1JK'9K#L2S*BK(^LIZ9F MNFX^L'K_ -;Z4WC4/X(V8A>[<,:UOEY7[!^*-9]AV=XDD_=:TT;)YOS5; 0G MZ(#Y,Q_N_9)QAFPDCQJ;OYMNO[GW4R^QZU?_ %+#6:V"6BW\:U5\SIXFE6LQ MZ+B46!];DF')*B#\?()(9B9DVD8N]B-:K8_((^/;6RZ1J]BV<0VRUBY\TF:Y M\@(2^CF8YXGB>8BOWZI/4[W\ZW>PO26[]SZ'YIVL*D;M66P6;_Z-JU[P!'8] M;WA"FR_::]<6CHG\QJW7"_ B^;F#\C[Q'$4$4LF&T_?'OGVNV_M1L>MZ]L_Z MAFKZ\)%6G^D9JM[9J9C&VK$>^WCT5P]:$-/_ "-'R\/$?(Y$9K;3M,V3%;/C M\A>QWHJ)FY[6_*IL\8;5>M<^"GFR?(S&/H9XYYGB(F>I#^X#T4;2W=N&V]J> MG(Z&Q/MCS8.=LZ2N91JZ5)91Q8BK-5+ Q2YNVXI="62:L=E:U<3MA%,C(*= MVJJQ'QI"O80$(!YY/=^WES(7GYC!PMK+1>RYCV,%1$_Q@2L56,F%3+N(ER6D MO_)R:S+SD(4FZZ3>]G?U>0=?]A43MK:M=(B5L*FK;8VBH'U@KR2<<#J"365@ MO?*MD.CBQX_:9C2'LBZ/#')/%CGC%QY>U;N-^,VK6[6TXG)Z+1RUD'$^]@\* M\\R^+,^=@%IJ8SWI.T4\V!6%6'3,Q8*8\NH6S ]P\BM>.LU\TZJN0@$W;8#3 M7ZXX"9-MCP.%Q_RY*62$?81S$=6=/4KZADO1?5>R#-UG5O9&[-^UN.H[)@3X M%%4BL:WRA*^YJ]"6<.">^@:3L"3KC82 ET;DS!<$N7#+DPQ)^F??7OU9[EYO M$+UQ5S$:YJUPK^'.Q(!DKN7@E\9FT"B8NJ2!4"\?5!CIKKEK&M-U@P5;6F:2 MO7J=HKY*M9#(J]%J%\S755X+FHLB$29!R4R]LB'F4"("(+&2K]]H_1OWQZ>[ MRYV=T=%N.T:$CL,E@U1<=6VI>AW=K.&7.?$%!84YK1"0^7KXOMUEMEM-U-PKR%2.9X6Q9&LC M((GU^U,F#5_\P!\Y&7">J[1WL7W,'VO!]I86W6^LMO::0:>JU>VU8JB*1,O9 M$W :_(:V60H:J.9+2>D"9GEPA?:*,_;,.(*"[V[+VEUYFC-[*,P-? M,X#8+.?NVL%4O&$-2&//%_)R5\/*V 6$/XI*LL2I9,\@7+I\YOI^/VB^.8'; MQO,IW:*J*57F)&?$I?%CUUT3PHI607D(>\4]Z^Q7>?5JV%[E^C!7 8FY8QF5G)5T5_>H-X[1;9WCUBU^9,I N=AQV-_\ *I0ZJJYXPF1ZPTKJ M:S""8/S!)"8Q73U->3ALUW'_&OMEK+,;I>"UO<\JL7MQ]2 M<3^MB=Y\O7$R:'MJ8#N#L61&QE[F0Q%8I M 7M^7\.12$?:ZE"DX1]A1SXFP0'RF38P^(&6^^X#U*D=XM/ZS:Z39@J]]]?D M$]:I.-S<&Y@;(U_,,#P71+-;#,3V CZ(U6*[K5L:?F0_O,[@5_S&+82&RR@^ MP??4>VV?S"-C2U^K[5:&YD?TZNOVXC*B;?7DZ=%?J4RL2W'6MT4^LOCC7.MR MRH"'3;=],G8*-0Z!B&1QBY2CWF7C:K3 \UVN+S,600"Q3C\H]DG#>!:1A6YT MOT,]Z]6B,ZPZZKW9C2^L[,T.7V<++;RVH:2!&=R<"V5S.Z1W%B-BL.&DE),IG8X<9(^%K0PC[8JNCKG<),%B:JLM0J-(A<,W01CQAD\-83%O,?" M1YEGQXDVQ]>!%/$[SZ)>G#V$Z [\]UVVXG&[-Y9S M.:R:*V*9C,S#1OV9J.*D=H\<%/V)*&*-TNBN9+(@9($!%D=>T;9L;L>+M6,= MQ3IY$3;9BS4D)2OV!#A7%B7>)Q(D(>$LB"B"B)B>KT_]?/FCUL+TO2]^O+JH MIZS]O-'TZK,M-ZY[0QW*Y[8YUN0_+D L;- %$RLM/J?UN UWV\$ 1N=*K2>) M&\EC)6_L9M-6.1N6"LUHD'19"4B8QFSK&'#$YO'H4=&KE_?8N_%EA>+24,$U".3$./4 M)2A2_6SB0]<^1<["/ MB7KUQOO65Q*7M:M'66"PEDJ@&7&GLY,':],_&!C;"$;,?DGW(?E,)KNK;QVK MSNMY)N4I9<0KC5;6^.BM9KD;V1,U6Y&J^1-4*,"(($"(IAH+9$0P9[)TOU) M^H.1=W::Z[ ;$L;+2PUXXSW:?;=F:RM>F7]%^[/_ ! %KBE5N>5PH='Q<8XT ML=-6:F:A,S!RL_(P([(0GR=Q,[^*MGMOD*VK8FHG8CQOCKBJ.&S%'8:N3D1^ M*S+Y&X(U[%=4\SD3L7+R[2X9%+S82F!V8*GW+7GT,R5IQ4(L!\AZ<59NRW=FS][$?7?3?5'A3UHHQ*G:;6LBLKP:0L-#$UDQL 7#SAOBU6)E*C@]GK_3T_MS3[9V M=LV#>??N.3!Z]:TG7IJV+51RK)UEV-G8X'%3K&*V6B0,U6_&^/*'V'O]29PW M+9]NQ+QE'#2&)K2!9',7H:"F@2X,EXX0D(:R)(5P/ZI9UGG^?\N?Z<^.G57#W$>D#:79C;;[M1U);IC[S M= %46T]-6A_Q58+*[2JQ$(=MH=D)RQ0"M&:0%<#8JU9PO&8YKYPFP4JOSCIU[+F6F4:?V6L&HE>*E,/3[CL?5X="R7()1^483JV9V^, MNQH$<@8@B?A!2CB9R!"?9O>GOOXLX'+/W7&W]/JYY\OLED*&(S1Y2 M'6A/Y+*]&*!!4M688P7,K5JS3]C(-D"QGE"FX3N1>JAA[",LRF$ N$/M4XK2 M*I_QBQ\OB6K7,#("QC!'Q'QC]H\65/31ZM&/KQUO=;/M1RAL?8+I*J]*M[&,4F&L]8XQQQ_TXXX_/]N../\>.9G^9YZ<.G6/CC^W'_GCIUGQTZX\88<<_/&&/'/'^_&/''/^/.>9_P"\_P#WUQQ' M_:.N7G'7/6.<>,OY9<<<\?\ /''/^?'/'\=..?YZ.,<,<>.?Z_/T\?/_OQ\^<\S_',\=./[_OK/QQ_;C_SSCIQUGQTZ/'3K M7PVJ-:K\KO*IHM51&;)&E%OS6MHUU:=VZ.89D9B?OJ.W5 M'H)U8Z3S7@KKGKP^EE[&F6R6XME?=@WS6#\2(&1B;ECF)C M$43S/SR>47SA%S'*]X[H[MW&'&AMV65D5X@6Q06G&8O' F7PN'G,8VG4]A,A M2XF#\@"!X4 'P$V)Q=8D%:D?>1V;-B3@)*0CFPYO$#)EQ(\%//[I M+B.)D_''S\_'\_Z?/^_Q_;_K^7'\O*_ZSG6?'3H\=.CQTZX_1AQS\\88\<_U M^?IX^?\ WX\YYG^.9XZ.G1XZ='CIT>.G1XZ='CIT>.G1XZ=' 5CIT>.G1XZ='CIT>.G1XZ='CIU__9 end XML 10 gnca-20200723_htm.xml IDEA: XBRL DOCUMENT 0001457612 2020-07-23 2020-07-23 0001457612 false 8-K 2020-07-23 GENOCEA BIOSCIENCES, INC. DE 001-36289 51-0596811 100 Acorn Park Drive 5th Floor Cambridge MA 02140 617 876-8191 false false false false Common stock, $0.001 par value per share GNCA NASDAQ false XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page Cover Page
Jul. 23, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 23, 2020
Entity Registrant Name GENOCEA BIOSCIENCES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36289
Entity Tax Identification Number 51-0596811
Entity Address, Address Line One 100 Acorn Park Drive
Entity Address, Address Line Two 5th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code 617
Local Phone Number 876-8191
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value per share
Trading Symbol GNCA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001457612
Amendment Flag false
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Cover Page Sheet http://www.genocea.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports gnca-20200723.htm gnca-20200723.xsd gnca-20200723_cal.xml gnca-20200723_def.xml gnca-20200723_lab.xml gnca-20200723_pre.xml gncaq2pr.htm gnca-20200723_g1.jpg http://xbrl.sec.gov/dei/2019-01-31 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "gnca-20200723.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "gnca-20200723_cal.xml" ] }, "definitionLink": { "local": [ "gnca-20200723_def.xml" ] }, "inline": { "local": [ "gnca-20200723.htm" ] }, "labelLink": { "local": [ "gnca-20200723_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnca-20200723_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnca-20200723.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnca", "nsuri": "http://www.genocea.com/20200723", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20200723.htm", "contextRef": "i375056cacb304e4d8c5fc0d02c603cbd_D20200723-20200723", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Cover Page", "role": "http://www.genocea.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnca-20200723.htm", "contextRef": "i375056cacb304e4d8c5fc0d02c603cbd_D20200723-20200723", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.genocea.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001457612-20-000120-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001457612-20-000120-xbrl.zip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end